Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析

◆英語タイトル:Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH66520FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Alexion Pharmaceuticals Inc (ALXN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alexion Pharmaceuticals Inc (Alexion) discovers, develops and markets therapies based on complement biology and inhibition for rare diseases. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. It also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc Key Recent Developments

Feb 04,2021: Alexion reports fourth quarter and full year 2020 results
Jan 12,2021: Alexion highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference
Dec 14,2020: AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
Oct 29,2020: Alexion reports third quarter 2020 results
Oct 06,2020: Alexion highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Alexion Pharmaceuticals Inc – Key Facts
Alexion Pharmaceuticals Inc – Key Employees
Alexion Pharmaceuticals Inc – Key Employee Biographies
Alexion Pharmaceuticals Inc – Major Products and Services
Alexion Pharmaceuticals Inc – History
Alexion Pharmaceuticals Inc – Company Statement
Alexion Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Alexion Pharmaceuticals Inc – Business Description
Product Category: Andexxa
Overview
Performance
Product Category: Kanuma
Overview
Performance
Product Category: Soliris
Overview
Performance
Product Category: Strensiq
Overview
Performance
Product Category: Ultomiris
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Others
Performance
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alexion Pharmaceuticals Inc – Corporate Strategy
Alexion Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Alexion Pharmaceuticals Inc – Strengths
Alexion Pharmaceuticals Inc – Weaknesses
Alexion Pharmaceuticals Inc – Opportunities
Alexion Pharmaceuticals Inc – Threats
Alexion Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 04, 2021: Alexion reports fourth quarter and full year 2020 results
Jan 12, 2021: Alexion highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference
Oct 29, 2020: Alexion reports third quarter 2020 results
Oct 06, 2020: Alexion highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day
Aug 25, 2020: Alexion Pharmaceuticals: Departure of directors or certain officer; election of directors
Aug 06, 2020: Alexion announces appointment of first Chief Diversity Officer
Jul 30, 2020: Alexion reports second quarter 2020 results
Jul 02, 2020: Alexion finalizes settlement with the U.S. Securities and Exchange Commission
Jul 02, 2020: SEC charges Alexion Pharmaceuticals with FCPA violations
Jun 17, 2020: Alexion Charitable Foundation announces first rare belonging grants
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Alexion Pharmaceuticals Inc, Key Facts
Alexion Pharmaceuticals Inc, Key Employees
Alexion Pharmaceuticals Inc, Key Employee Biographies
Alexion Pharmaceuticals Inc, Major Products and Services
Alexion Pharmaceuticals Inc, History
Alexion Pharmaceuticals Inc, Subsidiaries
Alexion Pharmaceuticals Inc, Key Competitors
Alexion Pharmaceuticals Inc, Ratios based on current share price
Alexion Pharmaceuticals Inc, Annual Ratios
Alexion Pharmaceuticals Inc, Annual Ratios (Cont...1)
Alexion Pharmaceuticals Inc, Annual Ratios (Cont...2)
Alexion Pharmaceuticals Inc, Interim Ratios
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alexion Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Global Sweeteners Holdings Ltd (03889):企業の財務・戦略的SWOT分析
    Global Sweeteners Holdings Ltd (03889) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Glenmark Pharmaceuticals Limited:企業のM&A・事業提携・投資動向
    Glenmark Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Glenmark Pharmaceuticals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Matsuda Sangyo Co Ltd (7456):企業の財務・戦略的SWOT分析
    Matsuda Sangyo Co Ltd (7456) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Providence Resources plc (PZQA):企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …
  • Bilim Pharmaceuticals:企業の戦略的SWOT分析
    Bilim Pharmaceuticals - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • J & J Snack Foods Corp:企業の戦略・SWOT・財務情報
    J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report Summary J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Printpack Inc:企業の戦略的SWOT分析
    Printpack Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • AS Eesti Gaas:企業の戦略的SWOT分析
    AS Eesti Gaas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Aurora Energy Pty Ltd:企業の戦略的SWOT分析
    Aurora Energy Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Oshkosh Corp (OSK):企業の財務・戦略的SWOT分析
    Oshkosh Corp (OSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sagent Pharmaceuticals Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sagent Pharmaceuticals Inc (Sagent), formerly Sagent Holding Co, a subsidiary of Nichi-Iko Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and manufactures injectable products. The company offers products such as amikacin sulfate injection, USP, ampicillin and sulbactam f …
  • ShaMaran Petroleum Corp (SNM):企業の財務・戦略的SWOT分析
    Summary ShaMaran Petroleum Corp (ShaMaran Petroleum), formerly Bayou Bend Petroleum Ltd is an independent oil and gas exploration and development company. The corporation explores, produces, and develops oil and gas assets. It holds interests and operates Atrush petroleum property located in Kurdist …
  • Alamo Group, Inc.:企業の戦略・SWOT・財務分析
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • MedImmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respi …
  • BTB Real Estate Investment Trust:企業の戦略・SWOT・財務分析
    BTB Real Estate Investment Trust - Strategy, SWOT and Corporate Finance Report Summary BTB Real Estate Investment Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Rabigh Refining & Petrochemical Co (2380):企業の財務・戦略的SWOT分析
    Rabigh Refining & Petrochemical Co (2380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • TherOx Inc:医療機器:M&Aディール及び事業提携情報
    Summary TherOx Inc (TherOx) is a medical device company that develops and commercializes SuperSaturated Oxygen (SSO2) therapies for treatment of heart attack. Its SSO2 therapy is designed to ameliorate progressive myocardial necrosis by minimizing microvascular damage in heart attack patients. TherO …
  • Repsol, S.A.:企業の戦略・SWOT・財務情報
    Repsol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Repsol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Quaterra Resources Inc (QTA):企業の財務・戦略的SWOT分析
    Summary Quaterra Resources Inc (Quaterra Resources) is a copper exploration company that acquires and operates copper projects. The company's activities include acquisition, exploration and development of gold, silver, and copper deposits in Canada. Its projects comprise Quaterra’s Yerington Copper …
  • Omnicom Group, Inc.:企業の戦略・SWOT・財務情報
    Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆